The revision to the diagnostic manual does away with the complex 
multiaxial organization in favor of a simpler chapter order of disorders.

Research to enhance understanding of SUDEP biology is critical for discovering clinical and molecular biomarkers that could help identify at-risk patients.

Developing drugs that selectively block specific sodium channels could be the holy grail of neuropathic pain treatment.

Genetically-engineered CGRP antibodies have proven effective in initial trials at reducing migraine days.

As the U.S. population ages, clinicians can expect to evaluate and treat more geriatric patients for sleep disorders.

Sleep-related breathing disorders are often underdiagnosed and need to be recognized and treated before harm comes to a patient or those around them.

Patients should be counseled on sleep hygiene before considering prescription sleep aides.

Omega-3 fatty acids, melatonin, and digestive enzymes are being investigated as potential treatments.

Identification, assessment and evaluation of concussions enables clinicians to determine a safe return date for young athletes.

Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.

Nonpharmacologic management across multidisciplinary teams is warranted due to lack of effective pharmacologic options to treat agitation.

In those older than age 65 years, high BP heightens risk for various forms of heart disease as well as for chronic kidney disease and diabetes mellitus.

Federal criminalization of the drug—most commonly used in the treatment
 of HIV, pain and glaucoma—has limited research into its effectiveness.

The advent of oral therapy now gives multiple sclerosis patients more options besides injections, which were the mainstay treatment.